Introduction: Study of crystal properties and polymorphism is a crucial area in product development and technology transfer for M.Pharm students. Understanding how a drug substance can exist in different crystalline forms affects solubility, dissolution, stability, manufacturability, and bioavailability. This blog-style MCQ set focuses on core concepts such as crystal lattices, packing, polymorphic transitions, thermodynamic relationships, analytical techniques (PXRD, DSC, IR, Raman), and practical implications for formulation, scale-up and regulatory control. These questions are designed to deepen comprehension, encourage critical thinking about solid-state problems encountered during development, and prepare students for real-world decision-making in pharmaceutical development and intellectual property considerations.
Q1. Which characterization technique provides direct information about the long-range order and unit cell parameters of a crystalline drug substance?
- Differential scanning calorimetry (DSC)
- Powder X-ray diffraction (PXRD)
- Infrared spectroscopy (IR)
- Thermogravimetric analysis (TGA)
Correct Answer: Powder X-ray diffraction (PXRD)
Q2. What term describes two or more crystalline forms of the same chemical substance with different arrangements or conformations in the crystal lattice?
- Isotropy
- Polymorphism
- Hydration
- Amorphism
Correct Answer: Polymorphism
Q3. Which of the following best indicates a monotropic relationship between two polymorphs?
- The forms convert reversibly at an equilibrium transition temperature
- One form is always more stable than the other at all temperatures below melting
- Both forms coexist at the transition temperature
- They show identical melting points
Correct Answer: One form is always more stable than the other at all temperatures below melting
Q4. Ostwald’s Rule of Stages predicts that during crystallization the first-formed solid is usually:
- The thermodynamically most stable polymorph
- An amorphous glassy phase
- The kinetically favored, less stable polymorph
- A stoichiometric solvate only
Correct Answer: The kinetically favored, less stable polymorph
Q5. Which solid-state technique measures heat flow associated with transitions such as melting, crystallization, and solid-solid transformations?
- Dynamic vapor sorption (DVS)
- Thermogravimetric analysis (TGA)
- Differential scanning calorimetry (DSC)
- Solid-state NMR
Correct Answer: Differential scanning calorimetry (DSC)
Q6. Which phenomenon directly impacts solubility and dissolution rate among polymorphs?
- Difference in optical rotation
- Difference in lattice energy and surface free energy
- Difference in molecular weight
- Difference in vapor pressure
Correct Answer: Difference in lattice energy and surface free energy
Q7. What is a cocrystal in the context of pharmaceutical solids?
- A crystal containing solvent molecules in the lattice
- A multicomponent crystal formed from an API and a coformer in a definite stoichiometric ratio
- A polymorph that forms only at high pressure
- A solid solution where API is amorphous
Correct Answer: A multicomponent crystal formed from an API and a coformer in a definite stoichiometric ratio
Q8. Which analytical method is most sensitive to detecting hydrate/solvate stoichiometry and loss of solvent on heating?
- Powder X-ray diffraction (PXRD)
- Thermogravimetric analysis (TGA)
- Polarized light microscopy
- Ultraviolet-visible spectroscopy (UV-Vis)
Correct Answer: Thermogravimetric analysis (TGA)
Q9. In solid-state screening for polymorphs, which parameter is commonly varied to discover new forms?
- Optical density of the sample
- Crystallization solvent, temperature, and rate of cooling
- Molecular weight of the API
- Ambient magnetic field
Correct Answer: Crystallization solvent, temperature, and rate of cooling
Q10. What does a shift in melting endotherm to a lower temperature in DSC typically suggest when comparing two polymorphs?
- The sample has become more crystalline
- The polymorph with lower melting is likely less thermodynamically stable
- Higher lattice energy for the lower-melting form
- That impurity-free material is present
Correct Answer: The polymorph with lower melting is likely less thermodynamically stable
Q11. Which term describes a crystal habit modification used to improve downstream processing such as flow and compressibility?
- Polymorph conversion
- Particle engineering or habit modification
- Co-crystallization
- Hydrate formation
Correct Answer: Particle engineering or habit modification
Q12. Which solid-state technique can provide information about molecular conformation and hydrogen bonding in crystals?
- Single crystal X-ray diffraction
- Optical microscopy without polarization
- High-performance liquid chromatography (HPLC)
- Milligram calorimetry
Correct Answer: Single crystal X-ray diffraction
Q13. Why is polymorph control critical for regulatory submissions and patent strategy?
- Polymorphs are irrelevant to drug safety
- Different polymorphs can lead to different bioavailability, stability, and may be separately patentable
- All polymorphs are treated equivalently by regulators
- Polymorphism only affects color of the final product
Correct Answer: Different polymorphs can lead to different bioavailability, stability, and may be separately patentable
Q14. Which of the following is a practical method to induce polymorphic transformation on a kilogram scale?
- Changing molecular formula by substitution
- Seeding with crystals of the desired polymorph during crystallization
- Increasing atmospheric pressure by 10 bar
- Running HPLC at different pH
Correct Answer: Seeding with crystals of the desired polymorph during crystallization
Q15. In a reversible enantiotropic polymorphic system, what happens at the transition temperature?
- The higher temperature form sublimates and disappears
- Both polymorphs have equal free energy and convert reversibly
- The more stable low-temperature form degrades chemically
- No thermal event is observed
Correct Answer: Both polymorphs have equal free energy and convert reversibly
Q16. Which phenomenon explains why mechanical milling can produce amorphous material or new polymorphs?
- Increase in lattice energy
- Induction of high defect density, increased surface energy and localized heating
- Reduction of molecular weight
- Selective solvent incorporation
Correct Answer: Induction of high defect density, increased surface energy and localized heating
Q17. What is the primary regulatory concern when an API converts to a less soluble polymorph during storage?
- Change in tablet color only
- Potential loss of bioavailability and altered therapeutic performance
- Improved manufacturability
- Increase in melting point without consequence
Correct Answer: Potential loss of bioavailability and altered therapeutic performance
Q18. Which approach is used to distinguish polymorphs that have very similar PXRD patterns due to peak overlap?
- Use of only visual color comparison
- Complementary techniques like solid-state NMR, Raman spectroscopy, and DSC
- Relying solely on melting point
- Measuring optical rotation
Correct Answer: Complementary techniques like solid-state NMR, Raman spectroscopy, and DSC
Q19. What is a solid solution in the context of crystalline pharmaceuticals?
- A physical mixture of two crystalline powders
- A homogeneous crystalline phase where minor components substitute into the host lattice
- A non-stoichiometric amorphous blend
- A crystal containing only solvent molecules
Correct Answer: A homogeneous crystalline phase where minor components substitute into the host lattice
Q20. During technology transfer, why must polymorph screening and control strategies be documented in the transfer dossier?
- To provide recipes for excipient procurement only
- To ensure reproducible manufacture, maintain product quality, and meet regulatory expectations about solid-state form
- Because polymorphism is not relevant post-approval
- To avoid any crystallization during formulation
Correct Answer: To ensure reproducible manufacture, maintain product quality, and meet regulatory expectations about solid-state form

I am a Registered Pharmacist under the Pharmacy Act, 1948, and the founder of PharmacyFreak.com. I hold a Bachelor of Pharmacy degree from Rungta College of Pharmaceutical Science and Research. With a strong academic foundation and practical knowledge, I am committed to providing accurate, easy-to-understand content to support pharmacy students and professionals. My aim is to make complex pharmaceutical concepts accessible and useful for real-world application.
Mail- Sachin@pharmacyfreak.com

